ArticleExperimental and therapeutic medicine2024

Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report.

Sujuan Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.